Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
Chronic liver disease questionnaire
Hepatic fibrosis
Metabolic associated fatty liver disease
Non-alcoholic fatty liver disease
Non-alcoholic steatohepatitis
Patient-reported outcomes
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
26
04
2020
revised:
17
06
2020
accepted:
01
07
2020
pubmed:
7
7
2020
medline:
26
8
2021
entrez:
7
7
2020
Statut:
ppublish
Résumé
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide and one of the leading causes of hepatocellular carcinoma and liver transplantation. Moreover, patients with NAFLD frequently complain of non-specific symptoms including fatigue, abdominal discomfort, as well as anxiety, and NAFLD is reported to affect patient-reported outcomes (PROs). Thus, for clarifying the total burden of NAFLD, it is crucial to assess all associated outcomes, including not only clinical and economic outcomes but also PROs. PROs are thought to reflect what is happening in one's daily life and is an important way patients and health-care professionals communicate. There are various instruments for the assessment of PROs. Recently, a NAFLD/non-alcoholic steatohepatitis (NASH)-specific instrument called "Chronic Liver Disease Questionnaire (CLDQ)-NAFLD/NASH" has been developed. CLDQ-NAFLD/NASH comprises six domains: (i) abdominal symptoms, (ii) activity/energy, (iii) emotional health, (iv) fatigue, (v) systemic symptoms, and (vi) worry. CLDQ-NAFLD/NASH has demonstrated excellent internal consistency, face validity, content validity, and test-retest reliability. It has been sufficiently validated in two international phase 3 clinical trials. In this review, we summarize features of various instruments for assessing PROs by focusing on CLDQ-NAFLD/NASH. We also examine the validity of CLDQ-NAFLD/NASH in Japanese patients and alterations in CLDQ-NAFLD/NASH score in Japanese patients with significant hepatic fibrosis. Moreover, we discuss the utility of CLDQ-NAFLD/NASH in phase 3 clinical trials and in a real-world clinical setting.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
629-636Informations de copyright
© 2020 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84.
Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int. 2017; 37: 81-84.
Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N. Engl. J. Med. 2017; 377: 2063-2072.
Wong RJ, Aguilar M, Cheung R et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015; 148: 547-555.
Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023.
Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat. Rev. Gastroenterol. Hepatol. 2019; 16: 411-428.
Cotter TG, Charlton M. Nonalcoholic steatohepatitis after liver transplantation. Liver Transpl. 2020; 26: 141-159.
Kim GA, Lee HC, Choe J et al. Association between non-alcoholic fatty liver disease and cancer incidence rate. J. Hepatol. 2017.
Peery AF, Dellon ES, Lund J et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012; 143: 1179-1187 e1173.
Madrazo BL. Diagnosis of nonalcoholic steatohepatitis without liver biopsy. Gastroenterol. Hepatol. (N Y). 2017; 13: 378-380.
Younossi ZM, Stepanova M, Anstee QM et al. Reduced patient-reported outcome scores associate with level of fibrosis in patients with nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 2019; 17: 2552-2560 e2510.
Younossi ZM. Patient-reported outcomes and the economic effects of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: the value proposition. Hepatology 2018; 68: 2405-2412.
Calvert M, Kyte D, Mercieca-Bebber R et al. Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension. JAMA 2018; 319: 483-494.
Eisen GM, Locke GR 3rd, Provenzale D. Health-related quality of life: a primer for gastroenterologists. Am. J. Gastroenterol. 1999; 94: 2017-2021.
Papaioannou D, Brazier J, Parry G. How valid and responsive are generic health status measures, such as EQ-5D and SF-36, in schizophrenia? A systematic review. Value Health 2011; 14: 907-920.
Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 1992; 30: 473-483.
Meregaglia M, Borsoi L, Cairns J, Tarricone R. Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia. Eur. J. Health Econ. 2019; 20: 181-193.
Sayiner M, Stepanova M, Pham H, Noor B, Walters M, Younossi ZM. Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. BMJ Open Gastroenterol. 2016; 3: e000106.
Chawla KS, Talwalkar JA, Keach JC, Malinchoc M, Lindor KD, Jorgensen R. Reliability and validity of the Chronic Liver Disease Questionnaire (CLDQ) in adults with non-alcoholic steatohepatitis (NASH). BMJ Open Gastroenterol. 2016; 3: e000069.
Younossi ZM, Stepanova M, Henry L et al. A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD. Liver Int. 2017; 37: 1209-1218.
Hiyama A, Katoh H, Sakai D, Tanaka M, Sato M, Watanabe M. Clinical impact of JOABPEQ mental health scores in patients with low back pain: analysis using the neuropathic pain screening tool painDETECT. J. Orthop. Sci. 2017; 22: 1009-1014.
Hewlett S, Dures E, Almeida C. Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness Therapy (Fatigue) (FACIT-F), Multi-Dimensional Assessment of Fatigue (MAF), Multi-Dimensional Fatigue Inventory (MFI), Pediatric Quality Of Life (PedsQL) Multi-Dimensional Fatigue Scale, Profile of Fatigue (ProF), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (VAS). Arthritis. Care Res. (Hoboken) 2011; 63: S263-S286.
Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J. Pain Symptom Manage. 1997; 13: 63-74.
Vogelzang NJ, Breitbart W, Cella D et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin. Hematol. 1997; 34: 4-12.
Strasser F, Palmer JL, Schover LR et al. The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study. Cancer 2006; 107: 2949-2957.
de Avila L, Weinstein AA, Estep JM et al. Cytokine balance is restored as patient-reported outcomes improve in patients recovering from chronic hepatitis C. Liver Int. 2019; 39: 1631-1640.
Peng JK, Hepgul N, Higginson IJ, Gao W. Symptom prevalence and quality of life of patients with end-stage liver disease: a systematic review and meta-analysis. Palliat. Med. 2019; 33: 24-36.
Ohashi K, Ishikawa T, Hoshi A et al. Relationship between sarcopenia and both physical activity and lifestyle in patients with chronic liver disease. J. Clin. Med. Res. 2018; 10: 920-927.
Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999; 45: 295-300.
Two R, Verjee-Lorenz A, Clayson D, Dalal M, Grotzinger K, Younossi ZM. A methodology for successfully producing global translations of patient reported outcome measures for use in multiple countries. Value Health 2010; 13: 128-131.
Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005; 41: 790-800.
Younossi ZM, Stepanova M, Younossi I, Racila A. Validation of Chronic Liver Disease Questionnaire for nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 2019; 17: 2093-2100 e2093.
US Department of Health and Human Services FDA Center for Drug Evaluation and Research laurie. burke@ fda. hhs. gov, US Department of Health and Human Services FDA Center for Biologics Evaluation and Research toni. stifano@ fda. hhs. gov, and US Department of Health and Human Services FDA Center for Devices and Radiological Health SXD@ cdrh. fda. gov. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual. Life Outcomes 2006; 4: 79.
Younossi ZM, Golabi P, Henry L. A comprehensive review of patient-reported outcomes in patients with chronic liver diseases. J. Clin. Gastroenterol. 2019; 53: 331-341.
Younossi ZM. Patient-reported outcomes for patients with chronic liver disease. Clin. Gastroenterol. Hepatol. 2018; 16: 793-799.
Gerber LH, Weinstein AA, Mehta R, Younossi ZM. Importance of fatigue and its measurement in chronic liver disease. World J. Gastroenterol. 2019; 25: 3669-3683.
Newton JL, Pairman J, Wilton K, Jones DE, Day C. Fatigue and autonomic dysfunction in non-alcoholic fatty liver disease. Clin. Auton. Res. 2009; 19: 319-326.
Newton JL, Jones DE, Henderson E et al. Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut 2008; 57: 807-813.
Mlynarsky L, Schlesinger D, Lotan R et al. Non-alcoholic fatty liver disease is not associated with a lower health perception. World J. Gastroenterol. 2016; 22: 4362-4372.
Pulixi EA, Tobaldini E, Battezzati PM et al. Risk of obstructive sleep apnea with daytime sleepiness is associated with liver damage in non-morbidly obese patients with nonalcoholic fatty liver disease. PLoS ONE 2014; 9: e96349.
Wiscombe S, Newton J, Day C, Gibson J, West S. Obstructive sleep apnoea is common in adults with biopsy-proven non-alcoholic fatty liver disease. Sleep Med. 2015; 16: 1026.
Qi JC, Huang JC, Lin QC et al. Relationship between obstructive sleep apnea and nonalcoholic fatty liver disease in nonobese adults. Sleep Breath. 2016; 20: 529-535.
Odens ML, Fox CH. Adult sleep apnea syndromes. Am. Fam. Physician 1995; 52: 859-866 871-852.
Ejaz SM, Khawaja IS, Bhatia S, Hurwitz TD. Obstructive sleep apnea and depression: a review. Innov. Clin. Neurosci. 2011; 8: 17-25.
Swain MG, Jones DEJ. Fatigue in chronic liver disease: new insights and therapeutic approaches. Liver Int. 2019; 39: 6-19.
Estep JM, Avila LD, Weinstein A et al. Polymorphism for serotonin receptor 5HTR2C is associated with cognitive performance and non-alcoholic fatty liver disease (NAFLD). Hepatology 2019; 70: 1324A.
Cervenka I, Agudelo LZ, Ruas JL. Kynurenines: tryptophan's metabolites in exercise, inflammation, and mental health. Science 2017; 357.
Younossi ZM, Stepanova M, Lawitz E et al. Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. Liver Int. 2018; 38: 1849-1859.
Patterson SL, Schmajuk G, Jafri K, Yazdany J, Katz P. Obesity is independently associated with worse patient-reported outcomes in women with systemic lupus erythematosus. Arthritis. Care Res. (Hoboken) 2019; 71: 126-133.
Jain A, Nguyen NH, Proudfoot JA et al. Impact of obesity on disease activity and patient-reported outcomes measurement information system (PROMIS) in inflammatory bowel diseases. Am. J. Gastroenterol. 2019; 114: 630-639.
Vissers PA, Falzon L, van de Poll-Franse LV, Pouwer F, Thong MS. The impact of having both cancer and diabetes on patient-reported outcomes: a systematic review and directions for future research. J. Cancer Surviv. 2016; 10: 406-415.
Zhi L, Qiaojun L, Yanbo Z. Development and validation of patient-reported outcomes scale for hypertension. International J. Qual. Health Care 2015; 27: 369-376.
Sumida Y, Okanoue T, Nakajima A. Japan Study Group of N. Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis. Hepatol. Res. 2019; 49: 1256-1262.
Younossi ZM, Ratziu V, Loomba R et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2019; 394: 2184-2196.
Loomba R, Lawitz E, Mantry PS et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial. Hepatology 2018; 67: 549-559.
Harrison SA, Wong VW, Okanoue T et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J. Hepatol. 2020 in press.
Younossi ZM, Stepanova M, Nader F et al. Patient-reported outcomes (PROs) in patients with non-alcoholic steatohepatitis (NASH) and compensated cirrhosis (CC): data from the STELLAR-4 Phase 3 Clinical Trial. Hepatology 2019; 70: 1119A-1120A #1864.
Younossi ZM, Stepanova M, Nader F et al. Assessment of patient-reported outcomes (PROs) in patients with non-alcoholic steatohepatitis (NASH) treated with obeticholic acid (OCA): results from REGENERATE phase 3 clinical trial. Hepatology 2019; 70: 1366A-1368A #2324.